Premium
High weekly intravenous doses of desferrioxamine in porphyria cutanea tarda
Author(s) -
ROCCHI E.,
CASSANELLI M.,
VENTURA E.
Publication year - 1987
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1987.tb04149.x
Subject(s) - porphyria cutanea tarda , medicine , deferoxamine , porphyria , adverse effect , dermatology
SUMMARY Two elderly patients with sporadic porphyria cutanea tarda (PCT) and severe associated diseases were treated with high weekly intravenous doses of desferrioxamine. This therapy proved more effective than slow subcutaneous desferrioxamine infusion and no adverse effect was recorded. We consider high dose intravenous desferrioxamine a suitable treatment for those PCT patients with severe associated diseases who are unable to apply the technique of subcutaneous desferrioxamine infusion. The iron‐chelating agent, desferrioxamine (DFX), administered by prolonged slow subcutaneous infusion using a portable micro‐syringe pump to patients with porphyria cutanea tarda (PCT) who cannot undergo phlebotomy on account of severe associated diseases, has been proved to be effective. 1 We have evaluated the results of weekly intravenous administration of higher doses of DFX in two elderly patients with PCT in order to establish the best route for DFX administration.